Methods for making proteins containing free cysteine residues
The present invention relates to novel methods of making soluble proteins having free cysteines in which a host cell is exposed to a cysteine blocking agent. The soluble proteins produced by the methods can then be modified to increase their effectiveness. Such modifications include attaching a PEG moiety to form pegylated proteins.
1. An isolated, monoPEGylated human erythropoietin protein, wherein said monoPEGylated erythropoietin protein comprises a polyethylene glycol attached to a cysteine residue that has been substituted at a human erythropoietin amino acid position selected from the group consisting of A1, P3, T26, K45, E89, Q115, E117, S126, A128, K154, and T163.
2. The isolated, monoPEGylated human erythropoietin protein of claim 1 , wherein said polyethylene glycol is selected from the group consisting of a linear polyethylene glycol and a branched polyethylene glycol.
3. The isolated, monoPEGylated human erythropoietin protein of claim 1 , wherein said polyethylene glycol is a cysteine-reactive polyethylene glycol.
4. The isolated, monoPEGylated human erythropoietin protein of claim 3 , wherein said polyethylene glycol is selected from the group consisting of: a maleimide-polyethylene glycol, a vinylsulfone-polyethylene glycol and an iodoacetyl-polyethylene glycol.
5. A multimer comprising two or more of the monoPEGylated erythropoietin proteins of claim 1 .
6. The isolated, monoPEGylated human erythropoietin protein of claim 1 , wherein a polyethylene glycol is attached to the amino acid at position 26 of said human erythropoietin.
7. The isolated, monoPEGylated human erythropoietin protein of claim 1 , wherein a polyethylene glycol is attached to the amino acid at position 126 of said human erythropoietin.
8. The isolated, monoPEGylated human erythropoietin protein of claim 1 , wherein a polyethylene glycol is attached to amino acid 1 of said human erythropoietin.
9. A method for treating a condition treatable with erythropoietin, comprising administering to a patient in need thereof an effective amount of a composition comprising the isolated, monoPEGylated human erythropoietin protein of claim 1 .
10. The isolated, monoPEGylated human erythropoietin protein of claim 1 , wherein a polyethylene glycol is attached to the amino acid at position 3 of said human erythropoietin.
11. The isolated, monoPEGylated human erythropoietin protein of claim 1 , wherein a polyethylene glycol is attached to the amino acid at position 115 of said human erythropoietin.
12. The isolated, monoPEGylated human erythropoietin protein of claim 1 , wherein a polyethylene glycol is attached to the amino acid at position 45 of said human erythropoietin.
13. The isolated, monoPEGylated human erythropoietin protein of claim 1 , wherein a polyethylene glycol is attached to the amino acid at position 117 of said human erythropoietin.
14. The isolated, monoPEGylated human erythropoietin protein of claim 1 , wherein a polyethylene glycol is attached to the amino acid at position 89 of said human erythropoietin.
15. The isolated, monoPEGylated human erythropoietin protein of claim 1 , wherein a polyethylene glycol is attached to the amino acid at position 128 of said human erythropoietin.
16. The isolated, monoPEGylated human erythropoietin protein of claim 1 , wherein a polyethylene glycol is attached to the amino acid at position 154 of said human erythropoietin.
17. The isolated, monoPEGylated human erythropoietin protein of claim 1 , wherein a polyethylene glycol is attached to the amino acid at position 163 of said human erythropoietin.
18. The isolated, monoPEGylated human erythropoietin protein of claim 1 , wherein said monoPEGylated erythropoietin protein has biological activity in vitro as measured by stimulation of proliferation of the Ut7/Epo cell line whose proliferation is stimulated in response to human erythropoietin
19. An isolated, monoPEGylated human erythropoietin protein, wherein said monoPEGylated erythropoietin comprises a polyethylene glycol attached to a cysteine residue that has been inserted after R166 in human erythropoietin.
20. The isolated, monoPEGylated human erythropoietin protein of claim 19 , wherein said polyethylene glycol is selected from the group consisting of a linear polyethylene glycol and a branched polyethylene glycol.
21. The isolated, monoPEGylated human erythropoietin protein of claim 19 , wherein said polyethylene glycol is a cysteine-reactive polyethylene glycol.
22. The isolated, monoPEGylated human erythropoietin protein of claim 21 , wherein said polyethylene glycol is selected from the group consisting of: a maleimide-polyethylene glycol, a vinylsulfone-polyethylene glycol and an iodoacetyl-polyethylene glycol.
23. A method for treating a condition treatable with erythropoietin, comprising administering to a patient in need thereof an effective amount of a composition comprising the isolated, monoPEGylated human erythropoietin protein of claim 19 .